Clinical Trial: Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093801) titled 'Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer' on July 09.

Brief Summary: This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.

Study Start Date: Sept. 23

Study Type: OBSERVATIONAL

Condition: Metastatic Castration Resistant Prostate Cancer

Recruitment Status: NOT_YET_RECRUI...